NCT05746039RecruitingPhase 1/2
Feasibility of Semaglutide in Advanced Lung Disease
Feasibility of Semaglutide Therapy for Weight Loss in Advanced Lung Disease: A Pilot Study
Source: ClinicalTrials.gov · Last updated 21 Apr 2026
Brief summary (registry, in English)
The goal of this clinical trial is to learn whether semaglutide, an FDA-approved treatment for diabetes and obesity, is feasible and tolerable in patients with advanced lung disease. The main question[s] it aims to answer are: 1. Are patients with advanced lung disease able to tolerate semaglutide therapy? 2. Are we able to titrate semaglutide therapy to a target weight? Participants will be asked to perform pulmonary function, physical function and body composition testing, as well as a blood draw before and after 12-weeks of semaglutide therapy. While on therapy, subjects will be surveyed regarding any adverse events or side effects.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 8 (estimated)
- First submitted
- 2 Feb 2023
- Start date
- 29 Jan 2024
- Primary completion date
- 28 Dec 2027
- Lead sponsor
- University of Pennsylvania
- NCT number
- NCT05746039
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 8
- From 29 Jan 2024 to the primary completion date, 28 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of weight loss medication in last 90 days
- Prior suicide attempt
Other illness
- Diabetes
- History of gastroparesis
- History of scleroderma
- Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia (type 2)
- Uncontrolled thyroid disease
- History of acute/chronic pancreatitis
Other
- Pregnant or Breastfeeding
- Recent weight loss
- Recent or chronic GI complaints
- Hospitalized at time of evaluation
- Suicidal ideation in last 90 days
- Presence of a pacemaker or defibrillator
Who the study is looking for
- Diagnosis of one of the following lung diseases: interstitial lung disease, sarcoidosis, chronic obstructive pulmonary disease, or pulmonary hypertension
- Age > 18
- BMI > 30 kg/m2
- Requires supplemental oxygen on exertion
- Stable treatment regimen X 90 days
- Use of disease-modifying therapy
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Pennsylvania Perelman School of Medicine Coordinator of this site? Confirm its status | Philadelphia | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.